MNOV ▼ -6.4% - MediciNova, Inc. $MNOV Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) Topline data by EOY 24-SEP-2026 06:04 AM ET